





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|----------------------|------------------------|-----------|
|  | Application Number | 10/501,029 | |
| | Filing Date | July 25, 2005 | |
| | First Named Inventor | Zita Jegesne Csakai | |
| | Art Unit | 1624 | |
| | Examiner Name | Kahsay Habte | |
| Total Number of Pages in This Submission | | Attorney Docket Number | CytRx/016 |

| ENCLOSURES (Check all that apply) | | |
|--|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of all non-US patent and cited references; Form SB/08A/B; Postcard |
| <div style="border: 1px solid black; padding: 5px; min-height: 50px;"> Remarks </div> | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|---|----------|--------|
| Firm Name | Fish & Neave IP Group of Ropes & Gray LLP | | |
| Signature |  | | |
| Printed name | Erika Takeuchi | | |
| Date | August 21, 2007 | Reg. No. | 55,661 |

| CERTIFICATE OF TRANSMISSION/MAILING | | | |
|---|---|------|-----------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: | | | |
| Signature |  | | |
| Typed or printed name | Andrew Shine | Date | August 21, 2007 |



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2007

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$180.00)

Complete If Known

| | |
|----------------------|---------------------|
| Application Number | 10/501,029 |
| Filing Date | July 25, 2005 |
| First Named Inventor | Zita Jegesne Csakai |
| Examiner Name | Kahsay Habte |
| Art Unit | 1624 |
| Attorney Docket No. | CytRx/016 |

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 06-1075 #004049-0022 Deposit Account Name: Fish & Neave IP Group of Ropes & Gray LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

| Application Type | FILING FEES | | SEARCH FEES | | EXAMINATION FEES | | Fees Paid (\$) |
|------------------|-------------|-----------------------|-------------|-----------------------|------------------|-----------------------|----------------|
| | Fee (\$) | Small Entity Fee (\$) | Fee (\$) | Small Entity Fee (\$) | Fee (\$) | Small Entity Fee (\$) | |
| Utility | 300 | 150 | 500 | 250 | 200 | 100 | |
| Design | 200 | 100 | 100 | 50 | 130 | 65 | |
| Plant | 200 | 100 | 300 | 150 | 160 | 80 | |
| Reissue | 300 | 150 | 500 | 250 | 600 | 300 | |
| Provisional | 200 | 100 | 0 | 0 | 0 | 0 | |

2. EXCESS CLAIM FEES

| Fee Description | Small Entity Fee (\$) | Small Entity Fee (\$) |
|---|----------------------------------|-----------------------|
| Each claim over 20 (including Reissues) | 50 | 25 |
| Each independent claim over 3 (including Reissues) | 200 | 100 |
| Multiple dependent claims | 360 | 180 |
| Total Claims - 20 or HP = _____ x _____ = _____ | Multiple Dependent Claims | |
| HP = highest number of total claims paid for, if greater than 20 | Fee (\$) | Fee Paid (\$) |
| Indep. Claims - 3 or HP = _____ x _____ = _____ | | |
| HP = highest number of independent claims paid for, if greater than 3 | | |

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets - 100 = _____ /50= _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): IDS filing under 37 CFR 1.17(p)

180.00

SUBMITTED BY

| | | | |
|-------------------|----------------|---|------------------------|
| Signature | | Registration No. 55,661 (Attorney/Agent) | Telephone 212-596-9000 |
| Name (Print/Type) | Erika Takeuchi | | Date August 21, 2007 |

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AmericanLegalNet, Inc.
www.FormsWorkflow.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zita Jegesne Csakai, et al.
Application No. : 10/501,029
Confirmation No. : 3625
Filed : July 25, 2005
For : Pharmaceutically Effective Compounds
Examiner : Kahsay Habte
Group Art Unit : 1624

New York, New York
August 21, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the documents listed in the accompanying PTO/SB/08A form. Copies of these documents, except U.S. patents, are enclosed herewith.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).


08/23/2007 SFELEKE1 00000015 061075 10501029
01 FC:1806 180.00 DA

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

Please charge our Deposit Account No. 06-1075 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to Deposit Account No. 06-1075, Order No. 004049-0022. A duplicate copy of this Statement is enclosed.

Dated: August 21, 2007

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Erika Takeuchi', written over a horizontal line.

Erika Takeuchi (Reg. No. 55,661)
Attorney for Applicants
c/o FISH & NEAVE IP GROUP
ROPES & GRAY LLP
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (212) 596-9090

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

| | |
|------------------------|---------------------|
| Application Number | 10/501,029 |
| Filing Date | July 25, 2005 |
| First Named Inventor | Zita Jegesne Csakai |
| Art Unit | 1624 |
| Examiner Name | Kahsay Habte |
| Attorney Docket Number | CytRx/016 |

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | | US- 4,404,384 | 09-13-1983 | Gebert, et al. | |
| | | US-4,187,220 | 02-05-1980 | Takacs et al. | |
| | | US-4,451,286 | 05-29-1984 | Martin et al. | |
| | | US- 5,147,879 | 09-15-1992 | Nagy, et al. | |
| | | US- 5,239,077 | 08-24-1993 | Bertok, et al. | |
| | | US- 5,278,309 | 01-11-1994 | Bertok, et al. | |
| | | US- 5,296,606 | 03-22-1994 | Nagy, et al. | |
| | | US- 5,328,906 | 07-12-1994 | Nagy, et al. | |
| | | US- 5,334,600 | 08-02-1994 | Van Duzer, et al. | |
| | | US- 6,649,628 | 11-18-2003 | Kurthy, et al. | |
| | | US- 6,653,326 | 11-25-2003 | Vigh, et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known) | | | | |
| | | CA 2059184 | 07/15/1992 | Ciba-Geigy AG | | |
| | | EP 0369944 | 05/23/1990 | Ciba-Geigy AG | | |
| | | GB 1,540,028 | 02/07/1979 | Hoechst Aktiengesellschaft | | |
| | | GB 1,582,029 | 12/31/1980 | Chinoin | | |
| | | WO 90/04584 | 05/03/1990 | Biorex | | |
| | | WO 90/08131 | 07/26/1990 | Chinoin | | |
| | | WO 92/03130 | 03/05/1992 | The Wellcome Foundation | | |
| | | WO 95/30649 | 11/16/1995 | Biorex | | |
| | | WO 97/00251 | 01/03/1997 | Biorex | | |
| | | WO 97/13504 | 04/17/1997 | Medgene Limited | | |
| | | WO 97/16439 | 05/09/1997 | Biorex | | |
| | | WO 98/06400 | 02/19/1998 | Biorex | | |
| | | WO 98/43948 | 10/08/1998 | Biorex | | |
| | | WO 00/35914 | 06/22/2000 | Biorex | | |
| | | WO 00/50403 | 08/31/2000 | Biorex | | |
| | | WO 01/79174 | 10/25/2001 | Biorex | | |
| | | WO 05/041965 | 05/12/2005 | Biorex | | |

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/501,029 |
| Filing Date | July 25, 2005 |
| First Named Inventor | Zita Jegesne Csakai |
| Art Unit | 1624 |
| Examiner Name | Kahsay Habte |
| Attorney Docket Number | CytRx/016 |

Sheet

of

NON PATENT LITERATURE DOCUMENTS

| Examiner initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| | | DeKoning, et al., "Org. 2766 improves Functional and Electrophysical Aspects of Regenerating Sciatic Nerve in the Rat," <i>Peptides</i> , 8(3):415-422, (1987) | |
| | | Morrison, et al., <i>Organic Chemistry</i> , Allyn and Bacon, Inc. (Boston), 205-211, (1983) | |
| | | Sorensen H. and Mortensen K., "Soluble expression of recombinant proteins in the cytoplasm of <i>Escherichia coli</i> ," <i>Microbial Cell Factories</i> , 4:1-8(2005) | |
| | | Stanley, "Sensory and Motor Nerve Conduction Velocities and the Latency of the H-Reflex During Growth of the Rat," <i>Experimental Neurology</i> , 71(2):497-506, (1981) | |
| | | Tesfamariam, et al., "Contraction of Diabetic Rabbit Aorta Caused by Endothelium-Derived PGH ₂ -TxA ₂ ," <i>American Journal of Physiology</i> , 257(5):1327-1333, (1989) | |
| | | Winslow, et al., "Comparative Effects of the Isomers of Bepridil on Isolated Coronary and Aortic Arteries," <i>European Journal of Pharmacology</i> , 166(2):241-249, (1989) | |
| | | Burger, Alfred, "Pro-Drugs," <i>A Guide to the Chemical Basis of Drug Design</i> , p. 15, 1.3.1 | |
| | | "Preparation and Spectral Study of O-methyl=benzamidoximes," Beltrao et al., <i>Chemical Abstracts</i> , 89:215038s (1978) | |
| | | "Insecticidal (hydroxyimino)butanones," Showa Denko K.K., <i>Chemical Abstracts</i> , 102:220443m (1985) | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.